<?xml version="1.0" encoding="UTF-8"?>
<p id="par0290">Anakinra® is an IL-1 receptor antagonist. As mentioned earlier, IL-6 seems to have a key role in the respiratory viral infections and in progression of pulmonary fibrosis. So Anakinra® has been suggested as possible adjunctive treatment. But, to the best of our knowledge, no in-vitro or clinical data are available [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0245" ref-type="bibr">49</xref>]
</p>
